A Phase 2 clinical trial of MRG-106 in mycosis fungoides (MF) patients.

Trial Profile

A Phase 2 clinical trial of MRG-106 in mycosis fungoides (MF) patients.

Planning
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs MRG 106 (Primary)
  • Indications Cutaneous T cell lymphoma; Mycosis fungoides; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Nov 2017 According to a miRagen Therapeutics media release, data from the study is anticipated in 2019/2020.
    • 17 Aug 2017 New trial record
    • 11 Aug 2017 According to a miRagen Therapeutics media release, company intends to initiate this trial in H2 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top